By Karen Blum
The year 2022 could see, for the first time, FDA-approved medications for nonalcoholic steatohepatitis (NASH). Semaglutide (Ozempic, Novo Nordisk), already approved for diabetes, and Lilly’s investigational diabetes drug tirzepatide are among the agents to watch, according to a poster presentation at the ASHP 2021 Midyear Clinical Meeting and Exhibition, held virtually.
JANUARY 7, 2022